Home Archives 2009 November

Monthly Archives: November 2009

Drug Patent Expirations for December 2009

TradenameApplicantGeneric NamePatent Number Patent Expiration
MIGRANALValeantdihydroergotamine mesylate5,169,849Dec 8, 2009
PHOTOFRINAxcan Scandipharmporfimer sodium5,145,863Dec 15, 2009
XENICALHoffmann La Rocheorlistat4,598,089*PEDDec 18, 2009
CEDAXSciele Pharma Incceftibuten dihydrate4,812,561Dec 20, 2009
OXILAN-300Guerbetioxilan4,954,348Dec 21, 2009
OXILAN-350Guerbetioxilan4,954,348Dec 21, 2009
DEFINITYLantheus Medclperflutren6,146,657Dec 22, 2009
ZANTAC 150Glaxosmithklineranitidine hydrochloride5,102,665*PEDDec 23, 2009
VALTREXGlaxosmithklinevalacyclovir hydrochloride4,957,924*PEDDec 23, 2009
ZIAGENGlaxosmithklineabacavir sulfate5,089,500*PEDDec 26, 2009
TRIZIVIRGlaxosmithklineabacavir sulfate; lamivudine; zidovudine5,089,500*PEDDec 26, 2009
EPZICOMSmithkline Beechamabacavir sulfate; lamivudine5,089,500*PEDDec 26, 2009
CORVERTPharmacia And Upjohnibutilide fumarate5,155,268Dec 28, 2009

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Courtesy of DrugPatentWatch.com

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.

This is my initial response to the Kyoto Prize, which I was able to attend on a fellowship from Point Loma Nazarene University. For more details on the Kyoto Prize see my previous post.

kyotoprizeI had an opportunity to interact with each of the laureates, and focused on the question of how it was that they were able to accomplish their exemplary achievements. It is not enough to simply be brilliant or hard-working — all their peers likely share these characteristics. What are the differentiating factors that enabled their unique achievements?

I am still working on an expanded discussion for more formal publication, and I’ll link to the article when it is available. However, not to leave you in suspense, I’ll note that I was surprised by how well the enabling factors aligned with each laureate’s field — technology, basic sciences, and arts and philosophy.

At a recent event on the comparative advantages of small molecule vs. biologic drugs, several themes emerged which led me to re-examine the question of whether the practice of medicine is capable of keeping pace with medical innovation.

As mentioned in a previous post, the majority of patients receiving the personalized medicine drug Herceptin had not been previously administered Herceptin’s diagnostic test. This is extremely important, as the diagnostic test can identify those patients most likely to benefit from the drug and exclude those who are likely to see no benefits (and will likely only get sicker as they rotate through an ineffective drug). For all the talk of the promise of personalized medicine, it appears that the gatekeepers — physicians and payers — are unaware of how to effectively prescribe¬† personalized drugs.

This is not a new phenomenon. Antibiotic drugs have seen their effectiveness drop due to overprescription, which led to the emergence and rapid spread of antibiotic-resistant bacteria.

So, just as mis-prescription of antibiotics took the shine off many lucrative drugs, mis-prescription of personalized medicines stands to likewise diminish their value. What is particularly surprising is that this is not a new trend. For all the advances in drug development over the decades since over-prescription of antibiotics was recognized as a problem, physicians and payers are still hard pressed to prescribe drugs effectively.

When I asked the panel of potential solutions to the problem, I was given a list of emerging technologies such as bioinformatics, e-health, centralized databases, etc. that could solve the problem; adding technology to a problem isn’t necessarily going to solve it, it may just make it a more expensive problem! In reality the solution already exists. All healthcare payers need to do is require prior authorization before prescribing Herceptin, which would require physician consultation, and require a positive result in the diagnostic test prior to reimbursement for the drug.

As with most simple solutions, I’m sure that this one has already been conceived. So why is it not being used? Could it be that healthcare payers are afraid they might end up having to use a litany of diagnostic tests on all cancer patients, thereby offsetting any potential costs savings? I look forward to your thoughts in the comments section below.

Drug Patent Expirations for November 2009

TradenameApplicantGeneric NamePatent Number Patent Expiration
ACULAR LSAllerganketorolac tromethamine5,110,493*PEDNov 5, 2009
ACULARAllerganketorolac tromethamine5,110,493*PEDNov 5, 2009
PREVPACTakeda Pharms Naamoxicillin; clarithromycin; lansoprazole4,628,098*PEDNov 10, 2009
PREVACID IVTakeda Pharms Nalansoprazole4,628,098*PEDNov 10, 2009
ACEONSolvay Pharmsperindopril erbumine5,162,362Nov 10, 2009
PREVACIDTakeda Pharms Nalansoprazole4,628,098*PEDNov 10, 2009
PREVACID NAPRAPAC 500 (COPACKAGED)Takeda Pharms Nalansoprazole; naproxen4,628,098*PEDNov 10, 2009
CARDENEEkr Therapnicardipine hydrochloride5,164,405Nov 17, 2009
TROVAN PRESERVATIVE FREEPfizeralatrofloxacin mesylate5,164,402Nov 17, 2009
RESCULAR Tech Ueno Ltdunoprostone isopropyl5,166,178Nov 24, 2009
ATROVENT HFABoehringer Ingelheimipratropium bromide5,766,573Nov 28, 2009
PROAIR HFATeva Globalalbuterol sulfate6,352,684Nov 28, 2009
QVAR 40Teva Globalbeclomethasone dipropionate5,766,573Nov 28, 2009
XOPENEX HFASepracorlevalbuterol tartrate6,352,684Nov 28, 2009
QVAR 80Teva Globalbeclomethasone dipropionate6,352,684Nov 28, 2009
PROAIR HFATeva Globalalbuterol sulfate5,766,573Nov 28, 2009
PROVENTIL-HFA3malbuterol sulfate6,352,684Nov 28, 2009
QVAR 40Teva Globalbeclomethasone dipropionate6,352,684Nov 28, 2009
QVAR 80Teva Globalbeclomethasone dipropionate5,766,573Nov 28, 2009

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Courtesy of DrugPatentWatch.com

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.